Skip to content
Open access

451. Investigating synaptic density in youth with cannabis use: preliminary findings from a [18F]SynVesT-1 PET imaging study

Sep 2026 · International Journal of Neuropsychopharmacology · Vol 29, pp. i171 - i171 · 0 citations

TL;DR

The pilot findings do not support a difference in synaptic density in youth that use cannabis regularly compared to those who do not, suggesting that lower synaptic density may be related to more chronic, long-term use of cannabis.

Abstract

Abstract Background Adolescence is a key period for neurodevelopment, marked by synaptic pruning. Preclinical studies show that repeated cannabinoid exposure can alter synaptic structure and synaptic protein markers (Oliva et al., 2024; Rubino et al., 2015). In adults, chronic cannabis use has been linked to lower synaptic density, but it remains unclear if this is seen in youth (D’Souza et al., 2020). Aims & Objectives Here, we investigate if regular cannabis exposure in youth is related to lower synaptic density in the brain compared to those with low use, leveraging Positron Emission Tomography (PET) imaging with the radiopharmaceutical [18F]SynVesT-1. We also aim to explore the relationship between cannabis use severity, use frequency, and synaptic density. Method A preliminary sample of healthy individuals aged 16-26 from the community were recruited to complete a PET scan with the radiopharmaceutical [18F]SynVesT-1. Magnetic Resonance Imaging (MRI) scans of each participant was used to delineate six corticolimbic regions of interest (ROIs). Time-activity curves were fitted using a simplified reference tissue model (SRTM-2) with the centrum semiovale (CS) as the reference region. Non-displaceable binding potential (BPnd) were compared between individuals. Timeline Followback for the last 90 days (TLFB-90) was used to delineate low (<1x/week) and regular (≥1x/week) cannabis use (Gabrys & Porath, 2019). Use severity was assessed using the Cannabis Use Disorder Identification Test (CUDIT), and use patterns were assessed with the Daily Sessions, Frequency, Age of Onset, and Quantity of Cannabis Use Inventory (DFAQ-CU). Results Twenty-five individuals (15M, 10F, 21.9 years) completed imaging scans. In total, nine reported regular use of cannabis, having used 69 ± 19.6 days out of 90 days. Sixteen individuals reported low use of cannabis, with approximately 3 ± 4.2 days of use. Regular cannabis users showed significantly earlier initiation patterns compared to those with low use, indicated by a higher DFAQ-CU age of onset composite z-score (Regular: z=-0.08 ± 1.1; low: z=-2.8 ± 1.1; p<0.001). Of the regular users, four of the nine met threshold for hazardous use, and two met criteria for potential cannabis use disorder based on CUDIT score (mean: 9.9 ± 4.8). There was no significant difference in [18F]SynVesT-1 tracer binding between low and regular cannabis users in all ROIs. There was also no difference seen in those who had CUDIT scores at or above threshold for hazardous use. Finally, there were no correlations with CUDIT score (ρ=-0.021 to ρ=-0.273) or TLFB score (ρ=-0.064 to ρ=-0.273) with synaptic density (p>0.05). Discussion & Conclusions Our pilot findings do not support a difference in synaptic density in youth that use cannabis regularly compared to those who do not. This contrasts reports of significant decreases in synaptic density in those with cannabis use disorder, suggesting that lower synaptic density may be related to more chronic, long-term use of cannabis. This may also suggest that pre-existing differences may occur in individuals with cannabis use disorder, thereby increasing vulnerability. The lack of differences observed may also be related to the small sample size; thus, future work will continue to assess differences in synaptic density in healthy youth with cannabis use.

Read PDF

Similar papers

Aug 2026

In vivo imaging of synaptic density in psychotropic-free adults with autism spectrum disorder: a [¹¹C]UCB-J PET study.

The observed association between [¹¹C]UCB-J SUVR and RRB severity serves as a hypothesis-generating indicator of synaptic involvement of the behavioral rigidity in ASD, and highlights the complexity of ASD-related synaptic pathology.

Masamichi Yokokura, Taishi Tamayama, Yosuke Kameno et al. · 0 citations
Open access Sep 2026

533. The transition to addiction: repeat dopamine D2/3 receptor PET scans in high-risk volunteers

Abstract Background One of the best-replicated findings in biological psychiatry is that people with substance use disorders (SUDs) have low dopamine D2/3 receptor availability. It remains controversial, however, whether this is a pre-existing vulnerability trait or an effect of heavy drug use. Aims & Objectives To add...

M. Nikolić, M. Iqbal, N. Palacio et al. · 0 citations
Open access Sep 2026

577. **Rafaelsen Award Presentation** Association between cortical serotonin release and cognitive function in schizophrenia: an in vivo [11C]Cimbi-36 PET study with a d-Amphetamine challenge

This is the first direct assessment of the relationship between serotonin release and cognition in schizophrenia and shows that neocortical serotonin release is directly associated with general intellectual function in schizophrenia.

M. Osugo, T. R. Marques, M. Veronese et al. · 0 citations
Review Open access Sep 2026

340. Synaptic density in psychiatric and neurodegenerative disorders: a systematic review of in vivo SV2A PET studies

This systematic analysis of SV2A PET studies across all brain disorders shows SD loss across disorders with disease-specific patterns, consistent with postmortem and genetic findings and regionally selective synaptic alterations within disorders point to circuit-level vulnerability rather than uniform global synaptic l...

G. Mirfallah, C. Schifani, D. Shateri et al. · 0 citations
Open access Sep 2026

506. The transition to psychopathology: repeat mGluR5 PET scans in high-risk volunteers

Abstract Background Type 5 metabotropic glutamate receptors (mGluR5) affect experience-dependent neuroplasticity and the readiness for future plasticity, influencing the ability to adapt to changing environments. Across drug- and stress-related disorders, the availability of these receptors is reported to be altered, b...

M. Nikolić, M. Iqbal, N. Palacio et al. · 1 citation
Open access Sep 2026

326. Ketamine-induced changes of cerebral glucose metabolism in healthy humans: evidence from [18F]FDG functional PET

The findings provide metabolic sensitive insight into ketamine’s impact on neuronal function and synchronous, temporally dynamic metabolic changes may contribute to ketamine’s rapid-onset and transient neuropsychological effects.

S. Graf, M. Reed, A. Mayerweg et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.